• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Alphatec files countersuit in NuVasive case against exec chair Miles

Alphatec files countersuit in NuVasive case against exec chair Miles

October 24, 2017 By Fink Densford

Alphatec Spine, Nuvasive

Alphatec (NSDQ:ATEC) this week announced a countersuit against NuVasive Inc. (NSDQ:NUVA) in response to charges levied at its recently joined exec chair Patrick Miles, who jumped ship from NuVasive to lead Alphatec in early October.

Earlier this month, NuVasive filed charges against Miles, claiming that he was involved in a year-long scheme to back Alphatec and discourage NuVasive from acquiring it, in addition to breaches of contract and violations of non-compete, non-solicitation and anti-poaching clauses.

In its countersuit, Alphatec claims that any non-compete restrictions placed on Miles are illegal and void in California, where NuVasive and Miles reside. The company goes on to express that it believes NuVasive not only knows about this legal issue, but was using the policy “advantageously in court against Globus Medical” in a case filed just over a week before Miles resigned, according to a spokesperson.

The suit also claims that Miles’ exit was driven by a significant “cultural divide” at the company which drove a number of senior members of the company to exit, and provides information on what it claims was a history of “alienating behavior” from NuVasive’s senior leadership which drove him to leave the company.

“By Summer 2017, it was clear to Mr. Miles that he no longer had any meaningful influence over NuVasive, or any other meaningful role there. Despite being listed on the NuVasive website’s Investor Relations page as an active member of “Executive Management” (A curious decision by NuVasive, about which Mr. Miles was, for a prolonged period of time, completely unaware), Mr. Miles participated in no Executive Committee meetings, no strategy meetings, and attended virtually no events involving surgeon customers. He had an ostensible office on-site at NuVasive, but rarely (if ever) went to the facility in an operational capacity. He began actively exploring opportunities, related to but outside the core spine industry, in an attempt to continue to utilize the skills he developed over his 25-year career, to maintain contact and relationships with surgeons and key opinion leaders in spine, and to build an innovative, high culture organization,” counsel for Alphatec argued, according to court documents.

In its countersuit, Alphatec asks for a jury trial and is seeking compensatory damages and legal costs alongside any other relief the court deems just and proper.

Filed Under: Business/Financial News, Legal News Tagged With: Alphatec, Nuvasive

More recent news

  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy